KBR Bags Patriot Missile System Services Contract from NSPA

Science, technology, and engineering solutions provider KBR (KBR) has won a services contract for the PATRIOT missile system from the NATO Support and Procurement Agency (NSPA). This includes analytical, engineering, Read More... The post KBR Bags Patriot Missile System Services Contract from NSPA appeared first on TipRanks Financial Blog.

KBR Bags Patriot Missile System Services Contract from NSPA

Science, technology, and engineering solutions provider KBR () has won a services contract for the PATRIOT missile system from the NATO Support and Procurement Agency (NSPA). This includes analytical, engineering, technical, programmatic, and logistics services.

The PATRIOT missile system, in use by a number of NATO countries globally, is an advanced surface-to-air guided air and missile defense system.

KBR Government Solutions President Byron Bright said, “We have a long history supporting NSPA and we are proud to continue this trusted relationship.” (See KBR stock chart on TipRanks)

Bright added, “KBR’s expertise in cutting-edge research will assist NSPA in responding to today’s dynamic threat environment in multiple theatres worldwide.”

The contract is for a period of three years with the option of two additional years. The scope of KBR’s deliverables includes systems engineering, program management, modeling and simulation, production, logistics, and deployment, among other services.

Notably, the company has provided advisory and assistance services for the PATRIOT system for over 40 years.

Recently, Cowen & Co. Analyst Gautam Khanna reiterated a Buy rating on the stock and increased the price target to $46 (20.5% upside potential) from $41.

Noting the company’s Q1 performance as in-line, Khanna commented, “Government Services underlying orders were better than optics of the reported book/bill. The stock is apt to grind higher as KBR’s premium growth is recognized by investors.”

Based on 6 Buys and 1 Hold, consensus on the Street is a Strong Buy. The average KBR analyst price target of $44.57 implies 16.8% upside potential. Shares are up 54.5% over the past year.

Related News:
Adobe Delivers Impressive Q2 Results; Shares Rise 3% After-Hours
JPMorgan to Acquire Nutmeg in U.K. Retail Expansion
BlackRock to Snap Up Baringa Partners’ Climate Change Scenario Model

The post KBR Bags Patriot Missile System Services Contract from NSPA appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

What's Your Reaction?

like
0
dislike
0
love
0
funny
0
angry
0
sad
0
wow
0

Next Article

JonesTrading Keeps a Buy Rating on CymaBay Therapeutics (CBAY)

In a report released today, Prakhar Agrawal from JonesTrading maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $8.00. The company's shares closed last Monday at $4.70. According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -5.3% and a 32.0% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Arcutis Biotherapeutics, and Aldeyra Therapeutics. Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $11.22, a 141.8% upside from current levels. In a report issued on June 9, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target. See today’s analyst top recommended stocks >> CymaBay Therapeutics' market cap is currently $319.5M and has a P/E ratio of -5.70. The company has a Price to Book ratio of 2.50. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA. The post JonesTrading Keeps a Buy Rating on CymaBay Therapeutics (CBAY) appeared first on TipRanks Financial Blog.

JonesTrading Keeps a Buy Rating on CymaBay Therapeutics (CBAY)

In a report released today, Prakhar Agrawal from JonesTrading maintained a Buy rating on CymaBay Therapeutics (CBAY – Research Report), with a price target of $8.00. The company's shares closed last Monday at $4.70.

According to TipRanks.com, Agrawal is a 1-star analyst with an average return of -5.3% and a 32.0% success rate. Agrawal covers the Healthcare sector, focusing on stocks such as Phathom Pharmaceuticals, Arcutis Biotherapeutics, and Aldeyra Therapeutics.

Currently, the analyst consensus on CymaBay Therapeutics is a Strong Buy with an average price target of $11.22, a 141.8% upside from current levels. In a report issued on June 9, Piper Sandler also maintained a Buy rating on the stock with a $12.00 price target.

CymaBay Therapeutics' market cap is currently $319.5M and has a P/E ratio of -5.70. The company has a Price to Book ratio of 2.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, focused on developing and providing access to therapies for patients with liver and other chronic diseases with high unmet medical need. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid. The company was founded on October 5, 1988 and is headquartered in Newark, CA.

The post JonesTrading Keeps a Buy Rating on CymaBay Therapeutics (CBAY) appeared first on TipRanks Financial Blog.

Source : Tip Ranks More   

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.